CURRENT OPINION IN PHARMACOLOGY

New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases.

Novel biologics targeting the P2X7 ion channel.

Focus on the essentials: tryptophan metabolism and the microbiome-gut-brain axis.

Recent advances of anti-cancer therapies including the use of cell-penetrating peptides.

P2X4 and lysosome fusion.

Pharmacological development in hidradenitis suppurativa.

State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis.

Pharmacological advances in pemphigoid.

Modern sun protection.

Trends in the treatment and prevention of keratinocyte carcinoma (non-melanoma skin cancer).

The race between drug introduction and appearance of microbial resistance. Current balance and alternative approaches.

Mucosal IgE immune responses in respiratory diseases.

The NIH microphysiological systems program: developing in vitro tools for safety and efficacy in drug development.

Targeting P2X4 and P2X7 receptors in multiple sclerosis.

The de-Alzheimerization of age-related dementias: implications for drug targets and approaches to effective therapeutics.

Clinical effectiveness of novel rosacea therapies.

Recent findings of molecules with anti-infective activity: screening of non-conventional sources.

Impaired cross-talk between NO and hyperpolarization in myoendothelial feedback: a novel therapeutic target in early endothelial dysfunction of metabolic disease.

Clinical trials of prion disease therapeutics.

Purinergic receptors and the inflammatory response mediated by lipids.

Autoimmunity in microbiome-mediated diseases and novel therapeutic approaches.

The gut microbiome and pharmacology: a prescription for therapeutic targeting of the gut-brain axis.

Fecal microbiota transplantation donation: the gift that keeps on giving.

Microfluidics for personalized drug screening of cancer.

The role of the P2X7 receptor in myeloid-derived suppressor cells and immunosuppression.

Pharmacological advances in pemphigus.

Pharmacological strategies for targeting platelet activation in asthma.

Therapeutic strategies for eosinophilic dermatoses.

Untangling human neurogenesis to understand and counteract brain disorders.

NG2 cells and their neurogenic potential.

Implementation of pre-clinical methodologies to study fibrosis and test anti-fibrotic therapy

P2X7 purinoceptor as a therapeutic target in muscular dystrophies.

Agonist-evoked endothelial Ca2+ signalling microdomains.

Peptides in clinical development for the treatment of brain tumors.

Pathology and natural history of organ fibrosis.

Understanding the effects of air pollution on neurogenesis and gliogenesis in the growing and adult brain.

Unravelling fibrosis using single-cell transcriptomics.

Role of the purinergic P2X receptors in osteoclast pathophysiology.

Bacterial peptidoglycans as novel signaling molecules from microbiota to brain.

Bacterial cross-resistance to anti-infective compounds. Is it a real problem?

Identification of anti-prion drugs and targets using toxicity-based assays.

Ependymal cells in the spinal cord as neuronal progenitors.

Rhythm on a chip: circadian entrainment in vitro is the next frontier in body-on-a chip technology.

Transcription inhibitors and inflammatory cell activity.

Nutrients and neurogenesis: the emerging role of autophagy and gut microbiota.

Advances in the epigenetics of fibroblast biology and fibrotic diseases.

More than cell wall hydrolysis: orchestration of cellular dynamics for organ separation.